Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized, Embedded, Multifactorial, Adaptive Platform Trial of Pathogen-Directed Precision Anti-inflammatory Therapy in Severe Community-Acquired Pneumonia(Core Protocal)

NCT07152587 is registered in ClinicalTrials.gov with Qingyuan Zhan as lead sponsor.

NCT NCT07152587
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07152587 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized, Embedded, Multifactorial, Adaptive Platform Trial of Pathogen-Directed Precision Anti-inflammatory Therapy in Severe Community-Acquired Pneumonia(Core Protocal)
Lead sponsor
Qingyuan Zhan
Phase
Phase 2/3
Overall status
Not yet recruiting
Start date
September 8, 2025
Completion date
December 31, 2035
Enrollment
1,500 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

severe community-acquired pneumonia (scap)